Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions

HIV Medicine

Volumn 11, Issue 9, 2010, Pages 545-553

  Rubio, R ^a   Serrano, O ^b   Carmena, J ^c   Asensi, V ^d   Echevarria S ^e   Flores, J ^f   Ribera, E ^g   Zarraga, M ^h   Ocampo, A ⁱ   de la Fuente, B ^j   Sepulveda M A ^k   Marino A I ^l   Minguez, C ^m   Vicent, R ^c   Carton J A ^d   Moyano, B ⁿ   Esteban, H ⁿ   Mahillo, B ^n,o   Serrano, L ⁿ   Gonzalez Garcia J ^n,p  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b BRISTOL MYERS SQUIBB   (United States)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL SAN AGUSTÍN   (Spain)

ⁱ HOSPITAL XERAL CÍES   (Spain)

^j HOSPITAL DE CABUEÑES   (Spain)

^k HOSPITAL VIRGEN DE LA SALUD   (Spain)

^l Universidad de La Coruña   (Spain)

^m HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁿ Fundacion Spanish Society of Infectious Diseases   (Spain)

^o National Transplant Organization (ONT)   (Spain)

^p HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

Antiretroviral therapy; Atazanavir; HIV infection

Indexed keywords

ATAZANAVIR; CHOLESTEROL; EMTRICITABINE; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PARAMETER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FASTING; FEMALE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OLIGOPEPTIDES; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR; TRANSAMINASES; TREATMENT OUTCOME; TRIGLYCERIDES; VIRAL LOAD;

EID: 77956401184     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00827.x     Document Type: Article

References (21)

1. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Maggiolo F, Ripamonti D, Suter F. Switch strategies in patients on effective HAART. J Antimicrob Chemother 2005, 55:821-823.
3. von Hentig N. Atazanavir/Ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 2008, 44:103-132.
4. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents., Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at, (accessed 2 December 2008)
5. Hammer SM, Eron JJ, Reiss P. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel. JAMA 2008, 300:555-570.
6. http://www.gesida.seimc.org/pcientifica/dcconsensos.asp?apnv0=pcientifica&apnvA=dcconsensosyrc&appag=dcconsensos_txt.htm, Panel de Expertos de GESIDA y Plan Nacional sobre el SIDA., Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2008). Available at, (accessed 2 December 2008)
7. Moyle G, Gatell J, Perno C-F. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDs 2008, 22:1-13.
8. Colafigli M, Di Giambenedetto S, Bracciale L. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med 2008, 9:172-179.
9. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006, 58:235-242.
10. Martinez E, Arnaiz JA, Podzamczer D. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003, 349:1036-1045.
11. Becker S, Rachlis A, Gill J. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - a prospective, randomized, multicenter, open-label study (DMP 049). Chicago, IL, 2001 [Abstract 20]
12. Raffi F, Bonnet B, Ferre V. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000, 31:1274-1278.
13. Negredo E, Cruz L, Paredes R. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002, 34:504-510.
14. Molina JM, Journot V, Morand-Jouber. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1 infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized study. J Infect Dis 2005, 191:830-839.
15. http://www.emea.europa.eu/humandocs/PDFs/EPAR/reyataz/H-494-PI-en.pdf, Summary of Product Characteristics., Reyataz. Available at, (accessed 2 December 2008)
16. Johnson M, Grinsztejn, Rodríguez C. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20:711-718.
17. Molina JM, Andrade-Villanueva J, Echevarria J. CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008, 23:646-655.
18. Mallolas J, Podzamczer D, Domingo P. Efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r-containing HAART: The ATAZIP study. Sydney, Australia, July 2007 [Abstract WEPEB117LB]
19. Molina JM, Andrade-Villanueva J, Echevarría J. Efficacy and safety of boosted once-daily atazanavir and twice-daily lopinavir regimens in treatment-naive HIV-1 infected subjects. CASTLE: 48 weeks results. Boston, MA, February 2008 [Abstract 37]
20. Moyle G, Andrade J, Girard PM. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 weeks primary analysis of the 96 weeks multicenter, open-label, randomized, prospective ReAL Study. Mexico City, August 2008 [Abstract MOPDB103]
21. Pineda JA, Santos J, Rivero A. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008, 61:925-932.